Radius Health provides update on oncology pipeline, RAD140 at SABCS
Radius Health announced updates from its oncology pipeline and its scientific presentations on elacestrant and RAD140 at the upcoming 2018 San Antonio Breast Cancer Symposium, or SABCS. The company's Phase 3 EMERALD study has been initiated and is now open for enrollment. The trial is a randomized, open label, active-controlled study evaluating elacestrant as second- or third-line monotherapy in advanced/metastatic ER-positive/HER2-negative breast cancer patients. Depending on the results, this single trial is intended to support applications for marketing approvals for elacestrant as a second- and third-line monotherapy in the U.S., European Union, and other markets. The company's Phase 1 dose escalation study of RAD140 in HR+ breast cancer patients is ongoing and enrollment is expected to remain active through Q1 of 2019. Radius has identified a provisional maximum tolerated dose and an additional cohort has been opened to further confirm tolerability, pharmacokinetics, and on-treatment pharmacodynamics effects of RAD140 at that dose.